POSTER PRESENTATION



Open Access

German evidence- and consensus-based guidelines 2011 for the treatment of juvenile idiopathic arthritis (JIA)

Gregor Dueckers^{5*}, Nihal Guellac⁵, Martin Arbogast⁸, Guenther Dannecker⁷, Ivan Foeldvari⁶, Michael Frosch¹⁴, Gerd Ganser¹¹, Arnd Heiligenhaus¹⁰, Gerd Horneff¹, Arnold Illhardt¹¹, Ruediger Krauspe¹², Matthias Schneider¹², Wolfram Singendonk², Helmut Sitter¹³, Barbara Markus³, Marianne Spamer⁴, Norbert Wagner⁹, Tim Niehues⁵

From 2011 Pediatric Rheumatology Symposium sponsored by the American College of Rheumatology Miami, FL, USA. 2-5 June 2011


Purpose

Standardisation of care opens the chance to further improve the quality of care for children and adolescents with JIA. We aimed to update our interdisciplinary, evidence-based clinical practice guidelines for the treatment of JIA. Our update is based on the existing German guide-lines of 1999[°] and 2005[°] and 2008[#] ([°]published as book chapters; [#]peer review publication in Clinical Research and Practice in Pediatrics 2008; 220: 392 - 402).

Methods

We performed a systematic literature analysis (deadline: 15th January 2010) in PUBMED with the key words "juvenile idiopathic (rheumatoid) arthritis" and "therapy". As limits in PUBMED we used: humans, published in the last 3 years, all child 0-18 years, clinical trial. Studies were evaluated for quality of methodology. Studies relating to diagnosis of JIA, uveitis, vaccination, transition and rofexocibe were excluded. Authors of the 2005 guideline and representatives attended consensus conferences, held on 9th of may 2007, 1st of August 2007 and 15th of January 2010 at Düsseldorf respectively Krefeld, Germany. Conferences were hosted by a professional moderator and were attended by 95 % of the representatives who had been named by interdisciplinary scientific societies. Scientific societies and organisations represented paediatricians in practice and hopistals, adult and pediatric rheumatologists, orthopaedics, ophthalmologists, surgeons, physiotherapists, national and local support-groups for parents and children. We edited a manuscript with core conclusions of

⁵HELIOS Klinikum, Krefeld, NRW, Germany



Results

The 2010 version of guideline inlcudes 15 statements. Updated consensus statements and key notes regarding drug therapy, symptomatic and surgical management of JIA were compiled and judged strictly by the criteria of Evidence-Based Medicine (EBM).

Conclusion

Many interventions in the treatment of JIA can now be based on high level evidence as the number of randomized controlled clinical trials is increasing: In a first step it is recommended that JIA is treated with NSAR followed by IATH and/or MTX. Other interventions such as the role of biological agents, physiotherapy, arthroscopy, etc. are discussed strictly on the basis of literature available. Complementing these data with the long-standing experience of caregivers allows to create recommendations that may improve the quality of care for children and adolescents with JIA.

Disclosure

Gregor Dueckers: Baxter, 9, Novartis Pharmaceuticals Corporation, 9; Nihal Guellac: None; Martin Arbogast: None; Guenther Dannecker: None; Ivan Foeldvari: Abbott Laboratories, 9, Chugai, 9, Pfizer Inc, 9; Michael Frosch: None; Gerd Ganser: None; Arnd Heiligenhaus: Abbott Immunology Pharmaceuticals, 2, Alcon, 2, Novartis Pharmaceuticals Corporation, 2; Gerd Horneff: Abbott Immunology Pharmaceuticals, 2, 5, 6, Bristol-Myers Squibb, 5, Chugai, 5, 6, Nycomed, 5, 6, Pfizer Inc, 2, 5, 6, 8, Sandoz,



© 2012 Dueckers et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Full list of author information is available at the end of the article

5, 6; Arnold Illhardt: None; Ruediger Krauspe: None; Matthias Schneider: None; Wolfram Singendonk: None; Helmut Sitter: None; Barbara Markus: None; Marianne Spamer: None; Norbert Wagner: None; Tim Niehues: Abbott Immunology Pharmaceuticals, 5, Essex Pharma, 5, Novartis Pharmaceuticals Corporation, 5, Pfizer Inc, 5, Wyeth Pharmaceuticals, 5.

Author details

¹Asklepios Kinderklinik, St. Augustin, NRW, Germany. ²Berufsverband, Berlin, Germany. ³Deutsche Rheuma Liga E.V., Bonn, NRW, Germany. ⁴Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen, Bayern, Germany. ⁵HELIOS Klinikum, Krefeld, NRW, Germany. ⁶Klinikum Eilbeck, Hamburg, HH, Germany. ⁷Olgahospital Stuttgart, Stuttgart, BW, Germany. ⁸RwTH Universitaetsklinikum, Aachen, NRW, Germany. ¹⁰St. Franziskus Hospital, Münster, NRW, Germany. ¹¹Universitaet Duesseldorf, Duesseldorf, NRW, Germany. ¹³Universitaet Muenster, Muenster, NRW, Germany. ¹⁴Universitaet Muenster, Muenster, NRW, Germany. ¹⁴Universitaet Muenster, Muenster, NRW, Germany. ¹⁴Universitaet Muenster, Muenster, NRW, Germany.

Published: 13 July 2012

doi:10.1186/1546-0096-10-S1-A53

Cite this article as: Dueckers *et al.*: **German evidence- and consensusbased guidelines 2011 for the treatment of juvenile idiopathic arthritis** (JIA). *Pediatric Rheumatology* 2012 **10**(Suppl 1):A53.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

BioMed Central

Submit your manuscript at www.biomedcentral.com/submit